-adenoma and cancer have monoclonal origin with subsequent subclonal evolution-adenoma and cancer showed a specific spectrum of heterogeneous somatic mutations-novel driver mutations that developed during adenoma and cancer evolution, in OR1B1 (GPCR signaling pathway) for adenoma evolution; LAMA1 (PI3K-Akt signaling pathway) and ADCY3 (FGFR signaling pathway) for CRC evolution. Here, OR1B1 is linked to cancer.